Standard
Occurrence of antibodies against natalizumab in relapsing multiple sclerosis patients treated with natalizumab. / Sørensen, Per Soelberg; Jensen, Poul Erik Hyldgaard; Haghikia, Aiden; Lundkvist, Malin; Vedeler, Christian; Sellebjerg, Finn; Koch-Henriksen, Nils; Fogdell-Hahn, Anna; Myhr, Kjell-Morten; Hillert, Jan; Gold, Ralf.
I:
Multiple Sclerosis, Bind 17, Nr. 9, 2011, s. 1074-8.
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Harvard
Sørensen, PS, Jensen, PEH, Haghikia, A, Lundkvist, M, Vedeler, C
, Sellebjerg, F, Koch-Henriksen, N, Fogdell-Hahn, A, Myhr, K-M, Hillert, J & Gold, R 2011, '
Occurrence of antibodies against natalizumab in relapsing multiple sclerosis patients treated with natalizumab',
Multiple Sclerosis, bind 17, nr. 9, s. 1074-8.
https://doi.org/10.1177/1352458511404271
APA
Sørensen, P. S., Jensen, P. E. H., Haghikia, A., Lundkvist, M., Vedeler, C.
, Sellebjerg, F., Koch-Henriksen, N., Fogdell-Hahn, A., Myhr, K-M., Hillert, J., & Gold, R. (2011).
Occurrence of antibodies against natalizumab in relapsing multiple sclerosis patients treated with natalizumab.
Multiple Sclerosis,
17(9), 1074-8.
https://doi.org/10.1177/1352458511404271
Vancouver
Sørensen PS, Jensen PEH, Haghikia A, Lundkvist M, Vedeler C
, Sellebjerg F o.a.
Occurrence of antibodies against natalizumab in relapsing multiple sclerosis patients treated with natalizumab.
Multiple Sclerosis. 2011;17(9):1074-8.
https://doi.org/10.1177/1352458511404271
Author
Sørensen, Per Soelberg ; Jensen, Poul Erik Hyldgaard ; Haghikia, Aiden ; Lundkvist, Malin ; Vedeler, Christian ; Sellebjerg, Finn ; Koch-Henriksen, Nils ; Fogdell-Hahn, Anna ; Myhr, Kjell-Morten ; Hillert, Jan ; Gold, Ralf. / Occurrence of antibodies against natalizumab in relapsing multiple sclerosis patients treated with natalizumab. I: Multiple Sclerosis. 2011 ; Bind 17, Nr. 9. s. 1074-8.
Bibtex
@article{9c27b7c566734763b4fee3e643db9553,
title = "Occurrence of antibodies against natalizumab in relapsing multiple sclerosis patients treated with natalizumab",
abstract = "In the clinical trials about 9% of natalizumab treated multiple sclerosis (MS) patients generated anti-natalizumab antibodies, of which 6% were persistent and 3% transient. The occurrence of antibodies reduced serum levels of natalizumab, decreased bio-efficacy, and abrogated the therapeutic efficacy.",
author = "S{\o}rensen, {Per Soelberg} and Jensen, {Poul Erik Hyldgaard} and Aiden Haghikia and Malin Lundkvist and Christian Vedeler and Finn Sellebjerg and Nils Koch-Henriksen and Anna Fogdell-Hahn and Kjell-Morten Myhr and Jan Hillert and Ralf Gold",
year = "2011",
doi = "http://dx.doi.org/10.1177/1352458511404271",
language = "English",
volume = "17",
pages = "1074--8",
journal = "Multiple Sclerosis Journal",
issn = "1352-4585",
publisher = "SAGE Publications",
number = "9",
}
RIS
TY - JOUR
T1 - Occurrence of antibodies against natalizumab in relapsing multiple sclerosis patients treated with natalizumab
AU - Sørensen, Per Soelberg
AU - Jensen, Poul Erik Hyldgaard
AU - Haghikia, Aiden
AU - Lundkvist, Malin
AU - Vedeler, Christian
AU - Sellebjerg, Finn
AU - Koch-Henriksen, Nils
AU - Fogdell-Hahn, Anna
AU - Myhr, Kjell-Morten
AU - Hillert, Jan
AU - Gold, Ralf
PY - 2011
Y1 - 2011
N2 - In the clinical trials about 9% of natalizumab treated multiple sclerosis (MS) patients generated anti-natalizumab antibodies, of which 6% were persistent and 3% transient. The occurrence of antibodies reduced serum levels of natalizumab, decreased bio-efficacy, and abrogated the therapeutic efficacy.
AB - In the clinical trials about 9% of natalizumab treated multiple sclerosis (MS) patients generated anti-natalizumab antibodies, of which 6% were persistent and 3% transient. The occurrence of antibodies reduced serum levels of natalizumab, decreased bio-efficacy, and abrogated the therapeutic efficacy.
U2 - http://dx.doi.org/10.1177/1352458511404271
DO - http://dx.doi.org/10.1177/1352458511404271
M3 - Journal article
VL - 17
SP - 1074
EP - 1078
JO - Multiple Sclerosis Journal
JF - Multiple Sclerosis Journal
SN - 1352-4585
IS - 9
ER -
